Last reviewed · How we verify
lamivudine or entecavir
Lamivudine and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication by inhibiting the reverse transcriptase enzyme of hepatitis B virus (HBV) and HIV.
Lamivudine and entecavir are nucleoside/nucleotide reverse transcriptase inhibitors that block viral replication by inhibiting the reverse transcriptase enzyme of hepatitis B virus (HBV) and HIV. Used for Chronic hepatitis B infection, HIV infection (lamivudine only, as part of combination antiretroviral therapy).
At a glance
| Generic name | lamivudine or entecavir |
|---|---|
| Also known as | LAM-RFA |
| Sponsor | Sun Yat-sen University |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) / Nucleotide reverse transcriptase inhibitor (NtRTI) |
| Target | Hepatitis B virus reverse transcriptase; HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Virology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Both drugs are nucleoside analogues that get incorporated into the growing viral DNA chain during HBV replication, causing chain termination and preventing further viral DNA synthesis. Entecavir is a guanosine analogue with higher potency and a higher genetic barrier to resistance compared to lamivudine. These agents reduce viral load and slow disease progression in chronic viral infections.
Approved indications
- Chronic hepatitis B infection
- HIV infection (lamivudine only, as part of combination antiretroviral therapy)
Common side effects
- Headache
- Fatigue
- Nausea
- Lactic acidosis
- Hepatomegaly
- Pancreatitis
Key clinical trials
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
- Halting Nucleoside Analogues in Chronic Hepatitis B (NA)
- Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant (PHASE2)
- Extension Study of Carvedilol RCT Study (NA)
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients
- A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase (PHASE3)
- Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B (PHASE2)
- Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- lamivudine or entecavir CI brief — competitive landscape report
- lamivudine or entecavir updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI